دورية أكاديمية
Biennial surveillance of Plasmodium falciparum anti-malarial drug resistance markers in Democratic Republic of Congo, 2017 and 2019
| العنوان: | Biennial surveillance of Plasmodium falciparum anti-malarial drug resistance markers in Democratic Republic of Congo, 2017 and 2019 |
|---|---|
| المؤلفون: | Yobi, D.M., Kayiba, N.K., Mvumbi, D.M., BOREUX, Raphaël, Kabututu, P.Z., Akilimali, P.Z., Situakibanza, H.N.T., De Mol, Patrick, Speybroeck, N., Mvumbi, G.L., Hayette, Marie-Pierre |
| المصدر: | BMC Infectious Diseases, 22 (1) (2022) |
| بيانات النشر: | BioMed Central Ltd |
| سنة النشر: | 2022 |
| المجموعة: | University of Liège: ORBi (Open Repository and Bibliography) |
| مصطلحات موضوعية: | Anti-malarial, Biennial, Democratic Republic of Congo, Markers, Plasmodium falciparum, Resistance, Surveillance, antimalarial agent, protozoal protein, cross-sectional study, Democratic Republic Congo, drug combination, drug resistance, genetics, human, malaria falciparum, Antimalarials, Cross-Sectional Studies, Democratic Republic of the Congo, Drug Combinations, Humans, Malaria, Falciparum, Protozoan Proteins, Human health sciences, Laboratory medicine & medical technology, Sciences de la santé humaine, Médecine de laboratoire & technologie médicale |
| الوصف: | peer reviewed ; Background: Because of the loss of chloroquine (CQ) effectiveness, the Democratic Republic of Congo (DRC)’s malaria treatment policy replaced CQ by sulfadoxine–pyrimethamine (SP) as first-line treatment of uncomplicated malaria in 2003, which in turn was replaced by artemisinin-based combination therapies (ACT) in 2005. The World Health Organization (WHO) recommends monitoring of anti-malarial drug resistance every 2 years. The study aimed to provide baseline data for biennial molecular surveillance of anti-malarial drug resistance by comparing data from a study conducted in 2019 to previously published data from a similar study conducted in 2017 in the DRC. Methods: From July to November 2019, a cross-sectional study was conducted in ten sites which were previously selected for a similar study conducted in 2017 across the DRC. P. falciparum malaria was diagnosed by a rapid diagnostic test (RDT) or by microscopy and dried blood samples (DBS) were taken from patients who had a positive test. Segments of interest in pfcrt and pfk13 genes were amplified by conventional PCR before sequencing. Results: Out of 1087 enrolled patients, 906 (83.3%) were PCR-confirmed for P. falciparum. Like in the 2017-study, none of the mutations known to be associated with Artemisinine (ART) resistance in Southeast Asia was detected. However, non-synonymous (NS) mutations with unknown functions were observed among which, A578S was detected in both 2017 and 2019-studies. The overall prevalence of pfcrt-K76T mutation that confers CQ-resistance was 22.7% in 2019-study compared to 28.5% in 2017-study (p-value = 0.069), but there was high variability between sites in the two studies. Like in 2017-study, the pfcrt 72–76 SVMNT haplotype associated with resistance to amodiaquine was not detected. Conclusion: The study reported, within 2 years, the non-presence of molecular markers currently known to be associated with resistance to ART and to AQ in P. falciparum isolated in the DRC. However, the presence of polymorphisms with ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1471-2334 |
| العلاقة: | urn:issn:1471-2334; https://orbi.uliege.be/handle/2268/295960Test; info:hdl:2268/295960; https://orbi.uliege.be/bitstream/2268/295960/1/6.pdfTest; scopus-id:2-s2.0-85124500647; info:pmid:35144535 |
| DOI: | 10.1186/s12879-022-07112-z |
| الإتاحة: | https://doi.org/10.1186/s12879-022-07112-zTest https://orbi.uliege.be/handle/2268/295960Test https://orbi.uliege.be/bitstream/2268/295960/1/6.pdfTest |
| حقوق: | open access ; http://purl.org/coar/access_right/c_abf2Test ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.8E0079C6 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 14712334 |
|---|---|
| DOI: | 10.1186/s12879-022-07112-z |